Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study
- Tison, Alice
- Quéré, Gilles
- Misery, Laurent
- Funck-Brentano, Elisa
- Danlos, François
- Routier, Emilie
- Robert, Caroline
- Loriot, Yohann
- Lambotte, Olivier
- Bonniaud, Bertille
- Scalbert, Camille
- Maanaoui, Sarah
- Lesimple, Thierry
- Martinez, Stéphanie
- Marcq, Marie
- Chouaid, Christos
- Dubos, Catherine
- Brunet-Possenti, Florence
- Stavris, Chloé
- Chiche, Laurent
- Beneton, Nathalie
- Mansard, Sandrine
- Guisier, Florian
- Doubre, Hélène
- Skowron, François
- Aubin, François
- Zehou, Ouidad
- Roge, Christophe
- Lambert, Mickaël
- Pham-Ledard, Anne
- Beylot-Barry, Marie
- Veillon, Rémi
- Kramkimel, Nora
- Giacchero, Damien
- Quatrebarbes, Julie De
- Michel, Catherine
- Auliac, Jean-Bernard
- Gonzales, Gilles
- Decroisette, Chantal
- Le Garff, Gwenaelle
- Carpiuc, Ioana
- Vallerand, Hervé
- Nowak, Emmanuel
- Cornec, Divi
- Kostine, Marie
DOIAbstract
International audienceImmune Checkpoint Inhibitors (ICI) for cancer therapy induce frequent Immune Related Adverse Effects (IRAE). Therefore, most patients with Preexisting Autoimmune Diseases (PAD) have been excluded from clinical trials. This study aims to evaluate the safety and efficacy of ICI in patients with PAD and cancer
Add to ORKG